These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1886657)

  • 21. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.
    Wang C; Lam KS; Ma JT; Chan T; Liu MY; Yeung RT
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):363-71. PubMed ID: 3427794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant prolactinoma.
    Berezin M; Gutman I; Tadmor R; Horowitz A; Findler G
    Acta Endocrinol (Copenh); 1992 Nov; 127(5):476-80. PubMed ID: 1471460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
    van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
    Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness analysis of two therapeutic methods for prolactinoma].
    Zhen JR; Yu Q; Zhang YH; Ma WB; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):257-61. PubMed ID: 18843964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional antitumoral effects of bromocriptine and radiotherapy in patients with prolactinomas or acromegaly.
    Coculescu M; Alessandrescu D; Stoica T; Simionescu N; Dimitriu V; Oprescu M; Chelmu S; Urba-Navicius V; Isbăşoiu O
    Endocrinologie; 1980; 18(4):277-88. PubMed ID: 7209360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
    Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
    Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas.
    Perrin G; Treluyer C; Trouillas J; Sassolas G; Goutelle A
    Pathol Res Pract; 1991 Jun; 187(5):587-92. PubMed ID: 1923955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A; Halse J; Bakke S; Bjøro T; Hansen E; Djøseland O; Brownell J; Jervell J
    Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alteration of prolactin secretion after transsphenoidal adenomectomy for prolactinomas].
    Yokoyama M
    No To Shinkei; 1990 Aug; 42(8):773-9. PubMed ID: 2223270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
    Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of hypophyseal prolactin-secreting macroadenomas].
    Candrina R; Tosoni M
    Recenti Prog Med; 1989 Sep; 80(9):471-3. PubMed ID: 2595078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromocriptine treatment of postoperative prolactinoma patients.
    Yang DY; Wang YC
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):346-50. PubMed ID: 8087709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.